{"name":"Formation Bio, Inc.","slug":"formation-bio-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ASN008","genericName":"ASN008","slug":"asn008","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"ASN008","genericName":"ASN008","slug":"asn008","phase":"phase_2","mechanism":"ASN008 is a small molecule that targets the SGLT1 transporter.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOUVpfcDNiUGZnelozQmZqTjd6aGxPZXBKa2s0cHVQa055WUthRGJab2pzTVZqVjNhLUxhQUJocmZLQVF6aVNtNXJJR1pXeWRhTEp1NkhqYVpXenBMMkViN3pYd3E5OEJ0SEpXM3ktaUFYZE9Wd3YyX0llSGhKNmhCX3phZ2NmUWpBYVNYZjQ5OGhQLWh5Y0RsQnFJUnM0enZFWTlTYkhUS0NLendHclJvRERn?oc=5","date":"2026-03-04","type":"deal","source":"Fierce Pharma","summary":"Sanofi strikes $1.5B global licensing deal for Sino Biopharm's first-in-class JAK/ROCK asset - Fierce Pharma","headline":"Sanofi strikes $1.5B global licensing deal for Sino Biopharm's first-in-class JAK/ROCK asset","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQcWpOczVNSGNvLUtWSHUwUmxCbGh5LXpuSzltdEp3aDZEYVg4UE1tZVlydFpZMmZpR0wzWURBSWZzSlhkdm5TVFE1S1pfcGdpbmtuQTAySnU4amU0aVg4WFU2T09adDNvNjBib3JYVEE2aEJDZlRUMElMb2VQWEtDSGl2bGl4eEthcVMtYlRuT0YxX1ZMazJ2VllHcmF5WjRXaEZQMl91WQ?oc=5","date":"2025-12-16","type":"pipeline","source":"BioWorld News","summary":"Formation loads new Bleecker division with Lynk’s TYK2 inhibitor - BioWorld News","headline":"Formation loads new Bleecker division with Lynk’s TYK2 inhibitor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE50UG5DMk5zZnJYTVVEN2g4aFY5aEV5QTRESzNpWnJlYXBhLWpPZ3g0YWtUd2hsWlJOeW01SlM5dDBIaVJXQkpXalRQa09NYlMyUEtKd2JxT0RzSGprWkNJc1paV3ZvRGhhVTRRM0kwd0s4SzVR?oc=5","date":"2025-12-11","type":"pipeline","source":"Pharmaceutical Technology","summary":"Formation Bio gains global rights to Lynk Pharma’s TYK2 inhibitor - Pharmaceutical Technology","headline":"Formation Bio gains global rights to Lynk Pharma’s TYK2 inhibitor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNVlVzaXpxcFNpenp2MXdKMW1EOGluYzBSRHFmV2k0d3oxbnQ5NGEzdDRsY3Q2WmN6SUd3T043c1VHVGlHeTNLR0x0N3BhQUpKRVg0RENoUDJWVTk5VjJJajdhc2xEZnZCODR3aEZmckIxanhObkszaHNBSUczcWhCaWFOTDN2RXdhaGptRGF1aGxEbWlGcWdrdko1SWppNE80VmtXZ0JJbWtqZw?oc=5","date":"2025-10-07","type":"pipeline","source":"BioSpace","summary":"BioSpace Honors 40 Under 40 Winners Whose Impact Reflects Industry’s Grit - BioSpace","headline":"BioSpace Honors 40 Under 40 Winners Whose Impact Reflects Industry’s Grit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPZWZmdEYtVlVNbTdNM0dFcVhYWU1SUFdRak0xd3JfZlF6Vk1Td2lod2ZmOTVxYkdZNkFTUDE1RDRzbHNCcmJFTjAtNC1CVnJlWjV4enp6V2p6dGNTQmg4ajRBZUpWVXQweHhhV0dfVjJlWG1HZEFMY0hIQ2pFdzBocUE4d1JfOGZjaGpMbW1QVWRxdw?oc=5","date":"2025-09-22","type":"pipeline","source":"Fierce Biotech","summary":"Introducing Fierce Biotech's 2025 Fierce 15 - Fierce Biotech","headline":"Introducing Fierce Biotech's 2025 Fierce 15","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxPTmR3WE1PZ1FPVWRHaXJ2X3VxVlFYNnItTVZyaURZUUFZSjlkYlowMFp5T1RwLU5RbUFmalg5Nm1BNjNueFIzT0RkMVhIMm9wZTdfRjB1NU1xejR6M0J5TkFZSDlEdmNLSTZBVGthYk5YTnZ0LUJtajd2dkdSWkcyUHBSckFtTWxaWGlCX0xoV01VQV96REl5a1dfM2xQTEFpYlkyVllneXVNMWMxaVBDNXI0MjQ0SkdkWmJSSDNMSFlNS1Y0RTZIcTJ2X0VVLUhueGtGMy1pSy1VMk4xcm1wVHRQaWsybDZNd2M1NUYyVnc3YUN4M1VCYmNCV0FLakxhazBV?oc=5","date":"2025-09-18","type":"pipeline","source":"PR Newswire","summary":"Formation Bio Expands Leadership Team With Top Biotech and Pharma Executives to Accelerate AI-Driven Drug Development - PR Newswire","headline":"Formation Bio Expands Leadership Team With Top Biotech and Pharma Executives to Accelerate AI-Driven Drug Development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5JTllYODNpRm1rMElVajh5Ujg4ZTI1VHk4bG5QMGRZYjR1RGFFSDFDcXZFcmhQeFNQdTlFM2o1cU9HdjhYS0NUa2V3aWlmTV9aMGUw?oc=5","date":"2025-07-29","type":"deal","source":"FirstWord Pharma","summary":"After in-licensing autoimmune mAb, Formation is in 'excellent position' for more deals - FirstWord Pharma","headline":"After in-licensing autoimmune mAb, Formation is in 'excellent position' for more deals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE15THdJbnVPcmN2b19FUWg4aWRWRFU1VlJDV0RYdW1wV1NCTjN5a0ZIOENSMnBMSUE3eEZUaEVEeUI5OEJzQmJTbFJpZ0g3SzFWNUlJ?oc=5","date":"2025-06-23","type":"deal","source":"FirstWord Pharma","summary":"Sanofi licenses Formation Bio's JAK/SYK inhibitor for up to €545M - FirstWord Pharma","headline":"Sanofi licenses Formation Bio's JAK/SYK inhibitor for up to €545M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE1DUVpwNEV4NGYwa0s4bWE5SXo1MWtSQmVrc0NURG5TZ3JXek9wbDRtMUFCdng4YTFyT2RTb3pWTGhMb3Zsc0FLdGNjYjhrZVdvX3R6a1o4cXQ2UGRpTVVhNmV2cUhZRU15Y0xlei1GMHl5ZF9TaG040gF8QVVfeXFMTmxJWE15a1JMSU1hS1VRRmJJRXlqWWxuNFBNb05fSUszN2lndzBQX21TMG40c3RiWkJHWXNNSHFrMGJOZ25oSHE3MEFvMDR5YThSUTluemtpbzdMMmZKN1I3dDEwTG1SNG00blR4Y0pFWjNuMjZvSWZaX1lmcQ?oc=5","date":"2025-06-10","type":"pipeline","source":"CNBC","summary":"37. Formation Bio - CNBC","headline":"37. Formation Bio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxNZFhlT3dTZmJVWlgzREVHVU1sX013NzJfdjJPYS1Va3FYTWFwWlJjWjZjdHRLWDNXNGtqLVM0NHJFWDY1UzNrQm0xUkJhSVM2dk1PTXNxamxYY2E2LW1HV3Y2aUJhYlRxQ2RJTThEd3hMekt5ZE5sb2o5anY4dnZNTlZqc09qZm14TFA2WS1OUEVDdnhQZzJoQjYzc1dRVi1BdFFCYzhsUHh4NFJPczBQcENQLVNkVTYyODlHUW9YbkNQaVhIME9TWjZ2c2pqeWVxT1JOc3lzTmVtVWJTQXYxTUU4OGFoc2V4cVNUMEN3S1hGc0xMOC1LeU44dVJUUWR1b0lZ?oc=5","date":"2025-06-09","type":"deal","source":"PR Newswire","summary":"Formation Bio Announces First Class of Entrepreneurs in Residence to Drive Pipeline Growth and Strategic Partnerships - PR Newswire","headline":"Formation Bio Announces First Class of Entrepreneurs in Residence to Drive Pipeline Growth and Strategic Partnerships","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQOFZiTUZJZXFRREJZRFh1bF9vakZOQzg5OUtjZmp5Z29SYVRUaVRPYmJfZU5BQjRCOGhRYVFYUFVweFcxWjRLVXVIZmowX09DdVJNaUp3MWg5QmlhdkNCeHlPZzROT2lVVl95S2tnMldjNjJCMG55X0NEakdFczdMZkVtTk8?oc=5","date":"2024-06-27","type":"pipeline","source":"Yahoo Finance","summary":"Formation Bio secures $372m funds for AI-driven drug platform - Yahoo Finance","headline":"Formation Bio secures $372m funds for AI-driven drug platform","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE5mZzkwVTZoUEtpTHpNZzRmWk1IaUpGemRVNWNaYWtaamVsak95VkNCWkdkWXJnaTFtcDFVcXVDZ2dpZlIzaDJnNkdTYW15SUNYLUo3azZOMGhnTEVrdVQ3YW16UVZIa2lj?oc=5","date":"2024-06-26","type":"pipeline","source":"Andreessen Horowitz","summary":"Investing in Formation Bio - Andreessen Horowitz","headline":"Investing in Formation Bio","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}